Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Galera Therapeutics ( (GRTX) ) has provided an update.
On October 15, 2025, Galera Therapeutics, Inc. and its subsidiary entered into an agreement with Biossil Inc. to sell their assets related to avasopasem and rucosopasem. The transaction includes an upfront payment of $3.5 million and potential future payments up to $105 million, impacting the company’s focus and financial strategy.
Spark’s Take on GRTX Stock
According to Spark, TipRanks’ AI Analyst, GRTX is a Underperform.
Galera Therapeutics exhibits significant financial instability with consistent losses and negative equity, heavily impacting its overall score. The technical analysis indicates bearish market momentum, and the valuation is unattractive with a negative P/E ratio. The absence of positive earnings call data or corporate events further contributes to the poor stock performance outlook.
To see Spark’s full report on GRTX stock, click here.
More about Galera Therapeutics
Galera Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of dismutase mimetic compounds, including avasopasem and rucosopasem, which are designed to protect normal tissues from damage by chemotherapy and radiation therapy.
Average Trading Volume: 72,935
Technical Sentiment Signal: Sell
Current Market Cap: $1.36M
See more data about GRTX stock on TipRanks’ Stock Analysis page.